Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results …
SA Springer, A Di Paola, MM Azar… - JAIDS Journal of …, 2018 - journals.lww.com
Objective: To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community …
SA Springer, A Di Paola, MM Azar, R Barbour… - 2018 - pubmed.ncbi.nlm.nih.gov
Objective To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
[HTML][HTML] Extended-Release Naltrexone Improves Viral Suppression among Incarcerated Persons Living with HIV with Opioid Use Disorders Transitioning to the …
SA Springer, A Di Paola, M Azar… - Journal of acquired …, 2018 - ncbi.nlm.nih.gov
Objective To determine if extended-release naltrexone (XR-NTX) would improve or maintain
viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorders …
viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorders …
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community …
SA Springer, A Di Paola, MM Azar… - Journal of Acquired …, 2018 - europepmc.org
Objective To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
[PDF][PDF] Extended-Release Naltrexone Improves Viral Suppression among Incarcerated Persons Living with HIV with Opioid Use Disorders Transitioning to the …
J Acquir Immune Defic Syndr, 2018 - academia.edu
Objective—To determine if extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results …
SA Springer, A Paola, MM Azar, R Barbour, BE Biondi… - 2018 - cabidigitallibrary.org
Objective: To determine whether extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
[PDF][PDF] Extended-Release Naltrexone Improves Viral Suppression among Incarcerated Persons Living with HIV with Opioid Use Disorders Transitioning to the …
J Acquir Immune Defic Syndr, 2018 - medicine.yale.edu
Objective—To determine if extended-release naltrexone (XR-NTX) would improve or
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …
maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use …